Argos Therapeutics focuses on the development and commercialization of individualized immunotherapies for cancer and infectious diseases. Its most advanced product, Rocapuldencel-T, is being evaluated in a clinical trial for metastatic renal cell carcinoma. The company has a partnership with Hong Kong firm Lummy for Rocapuldencel-T in China and other territories. Argos has faced financial pressure: its stock fell 65 percent in one day in February 2017 and the company has not received FDA approval for any drug since its establishment in 1997. In November 2017 Argos received $1.8 million from TKC Properties selling a building that housed one of the company’s facilities, funds the company said will allow it to last through June. At the time of the filing its stock traded around 16–17 cents per share. Argos Therapeutics develops fully personalized immunotherapies via its Arcelis™ technology, which captures mutated and variant antigens specific to each patient’s disease and is aimed at multiple cancers and infectious diseases. The company’s lead candidate, AGS-003, has initiated a pivotal Phase 3 ADAPT trial for metastatic renal cell carcinoma (mRCC). Argos recently raised additional funding to support that trial and to advance its clinical programs. The company raised an additional $17.5M in Series E financing, bringing total committed Series E funds to $60M. Argos is led by president and CEO Jeff Abbey and is based in Durham, North Carolina. Its AGS-004 candidate recently completed enrollment of a Phase 2b study for HIV. Argos Therapeutics leverages its Arcelis technology platform to develop personalized immunotherapies for the treatment of cancer and infectious diseases. Its lead product candidate, AGS-003, has initiated a pivotal Phase 3 study for metastatic renal cell carcinoma (mRCC). The company also develops AGS-004 for the treatment of HIV and expects Phase 2b data in the first half of 2014. Argos intends to use proceeds from the financing to support the Phase 3 clinical study of AGS-003. In August 2013 the company secured $42.5M in Series E financing, providing near-term capital to advance its clinical programs. Jeff Abbey serves as President and Chief Executive Officer. Argos Therapeutics is a Durham, North Carolina-based biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies using its Arcelis™ technology platform. The Arcelis platform uses biological components from each patient and employs the patient’s dendritic cells to activate an immune response specific to the patient’s disease. The company’s most advanced product candidates are AGS-003 for metastatic renal cell carcinoma (mRCC) and AGS-004 for HIV. Research and development are led by Charles Nicolette, Ph.D., chief scientific officer and vice president of R&D. Argos raised $25M in a Series D financing and intends to use the proceeds to support the planned commencement of its Phase 3 ADAPT study in newly diagnosed mRCC patients in mid-2012.

Total raised

$87M

Funding rounds

4

Latest round

Equity

Latest activity

Jan 2018